---
layout: post
title: "Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers; Guidance for Industry; Availability"
date: 2026-02-05 19:08:15 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-03186
original_published: 2024-02-15 00:00:00 +0000
significance: 8.00
---

# Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers; Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 15, 2024 00:00 UTC
**Document Number:** 2024-03186

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Charging for Investigational Drugs Under an IND: Questions and Answers." This guidance addresses frequently asked questions related to the implementation of FDA's regulation on charging for investigational drugs under an investigational new drug application (IND) for the purpose of either clinical trials or expanded access for treatment use. This guidance finalizes the revised draft guidance of the same title issued on August 23, 2022, and replaces the final guidance issued on June 3, 2016.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/02/15/2024-03186/charging-for-investigational-drugs-under-an-investigational-new-drug-application-questions-and)
- API: https://www.federalregister.gov/api/v1/documents/2024-03186

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
